47
views
0
recommends
+1 Recommend
1 collections
    1
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Akkermansia muciniphila: a promising target for the therapy of metabolic syndrome and related diseases

      research-article
      1 , 1 ,
      Chinese Journal of Natural Medicines
      Elsevier BV
      Gut microbiota, Metabolic syndrome, Diabetes, Atural medicine

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The probiotic Akkermansia muciniphila ( A. muciniphila) is an intestinal bacterium that was first identified in human feces in 2004. Its specialization in mucin degradation makes it a key microorganism that maintains intestinal mucosal barrier function. As an unique representative strain of the phylum Verrucomicrobia that can be cultured in vitro, A. muciniphila is much easier to detect by metagenomic analysis of intestinal flora. In the past few years, A. muciniphila has been getting increasing attention for the positive correlation between its intestinal colonization and host homeostatic metabolism. In this review, we summarize the relationship between A. muciniphila and host health and diseases, especially focusing on metabolic diseases and related mechanisms, as well as the natural food and drug-derived substrates affecting its colonization in the host, expecting to provide evidence and clues for the development of drugs targeting A. muciniphila.

          Author and article information

          Journal
          CJNM
          Chinese Journal of Natural Medicines
          Elsevier BV
          1875-5364
          20 November 2019
          : 17
          : 11
          : 835-841
          Affiliations
          [1] 1 Molecular Immunology and Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100000, China
          Author notes
          *Corresponding author: ZHANG Xiao-Wei, E-mail: zhxw@ 123456imm.ac.cn

          These authors have no conflict of interest to declare.

          Article
          S1875-5364(19)30101-3
          10.1016/S1875-5364(19)30101-3
          31831130
          9710dc6c-7a30-4ea3-9b92-5ec900bd91c2
          Copyright © 2019 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.
          History
          : 29 September 2019
          Funding
          Funded by: National Key R&D Program of China
          Award ID: 2017YFA0205400
          Funded by: National Natural Science Foundation of China
          Award ID: 81773800
          Funded by: National Drug Innovation Major Project of China
          Award ID: 2018ZX09711001-003-009
          Funded by: Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences
          Award ID: 2016-I2M-1-010
          This work was supported by the National Key R&D Program of China (No. 2017YFA0205400), the National Natural Science Foundation of China (No. 81773800), National Drug Innovation Major Project of China (No. 2018ZX09711001-003-009), Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (No. 2016-I2M-1-010).
          Categories
          Research article

          Medicine,Pharmaceutical chemistry,Pharmacology & Pharmaceutical medicine,Complementary & Alternative medicine
          Atural medicine,Gut microbiota,Metabolic syndrome,Diabetes

          Comments

          Comment on this article